Safety Assessment of Palm Tocotrienol (EVNol SupraBio™) in Subjects with Metabolic Syndrome

Safety Assessment of Palm Tocotrienol (EVNol SupraBio™) in Subjects with Metabolic Syndrome

A randomized, double-blind, cross-over and placebo-controlled clinical trial shows that in subjects with metabolic syndrome, supplementation with 400mg palm tocotrienol complex for 14 days are well-tolerated, with no signs of any adverse health events of blood profile (e.g. haematoxicity) and liver functions (e.g. hepatotoxicity). These results may contribute to the scientific community in the establishment of intake recommendations for tocotrienols, particularly the tolerable upper intake levels.

In this study, 31 subjects with metabolic syndrome aged 25-56 year-old were randomized to receive either 400mg of palm tocotrienol complex (EVNol SupraBio™, supplied by ExcelVite) or placebo for 14 days followed by measurement of body weight, haematological profile (ie: physiology of the blood) and liver functions examination. When compared to placebo, subjects supplemented with EVNol SupraBio™ (patented bio-enhanced natural full spectrum palm tocotrienol complex) demonstrate no negative effects on red blood cells (RBC), white blood cells (WBC) and platelet counts. Additionally, patients under EVNol SupraBio™ treatment did not show significant difference in body weight, and serum liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) and albumin. Collectively, EVNol SupraBio™ is well tolerated with no toxicity issue such as no report of weight loss, bleeding tendency or interference with the haemostasis status. In addition, EVNol SupraBio™ also does not affect liver function nor increase the risk of hepatotoxicity.

“Apart from this study, another recent clinical study also reveals that daily supplementation of 400mg of d-mixed tocotrienol (EVNol SupraBio™) for 52 weeks demonstrates fatty liver amelioration in non-alcoholic-induced fatty liver subjects, without any reported adverse health effects1. Fatty liver is the precursor to metabolic syndrome (eg. diabetes, obesity and hypertension) and these encouraging clinical results allows companies to formulate a liver health product with EVNol SupraBio™ to address fatty liver,” says CheeYen Lau, Nutritionist of ExcelVite.

“Not all tocotrienol are created equal. In fact, EVNol SupraBio™ – manufactured by ExcelVite is the only GMP-certified tocotrienol complex in the world. EVNol SupraBio™ has been used in more than 15 human clinical studies for different endpoints and health benefits such as brain protection, cardiovascular health (e.g. healthy cholesterol level and arterial compliance), liver health as well as skin and hair growth. This is the first human clinical study that evaluates the safety of tocotrienol in terms of haematological and hepatological profiles vis a vis proven safety results of EVNol SupraBio™,” added Lau.

Sources:

  1. Magosso E, et al. (2013, Dec 27). Tocotrienols for normalisation of hepatic echogenic response in nonalcoholic fatty liver: a randomised placebo-controlled clinical trial . Nutr J., 12(1), 166.
  2. Gan LY, et al. (2016). Safety Assessment of Tocotrienol Supplementation in Subjects with Metabolic Syndrome: A Randomized Control Trial. Journal of Oil Palm Research; Vol.28 (1) March 2016p.34-43.

For more information about tocotrienol, please visit the Tocotrienol Educational Website www.tocotrienol.org

Disclaimer : The statements in the above article have not been evaluated by the Food and Drug Administration. They are not intended to diagnose, treat, cure or prevent any disease.